Funding dedication helps take away boundaries to life-saving know-how for Canadians dwelling with sort 1 diabetes



3 “Strong Buy” stocks below $ 10 with triple digit upside potential

You don’t have to pay three-digit amounts to find compelling investment opportunities. It’s time to think outside the box at some cheap stocks that top analysts are cheering right now. Among the stocks that raise their thumbs up are three that have a highly attractive profile for retail investors: an initial price below $ 10 per share, a strong buy rating off the road, and triple-digit upside potential. We used the TipRanks database to look up these holdings and find out what else makes them so compelling. Let’s take a closer look. RedHill Biopharma (RDHL) The first stock we consider, RedHill Biopharma, is a biopharmaceutical company that focuses its research efforts on gastrointestinal diseases. The company has an active line of products – 6 drug candidates in clinical research and development and three products that are approved in the US or worldwide and are currently in the commercialization process. The three approved drugs are Movantik, a treatment for opioid-induced constipation (a common side effect) that is approved for use worldwide but only in Europe, Canada, and Israel; Talicia, a treatment for H. pylori infection (a common cause of stomach ulcers) that was approved by the FDA in November 2019; and Aemcolo, a treatment for “traveller’s diarrhea,” licensed for use in the United States only. These three drugs saw prescriptions and market share increases in 2020. For the full year, RedHill had revenues of $ 64 million with gross income of $ 27.5 million. In March of this year, the company reported cash on hand of $ 100 million. With a lot of cash and a profitable line of products, RedHill is in a solid position to continue its development activities. The company has several novel therapeutics in the pipeline as potential treatments for COVID-19. These include opaganib, which is in an ongoing phase 2/3 study in hospital patients. RHB-107, which is also in an ongoing phase 2/3 study, but for out-of-hospital patients. The clinical pipeline also includes RHB-204, which is in a phase 3 study for the treatment of pulmonary NTM disease. All of this caught the attention of HC Wainwright analyst Raghuram Selvaraju, who titled his opening report for this stock titled “A Trifecta of Pipeline Punched Products.” “In our view, RedHill is building the next leading gastroenterology-focused specialty pharmaceuticals franchise in the US market while expanding an extensive pipeline of fast-maturing drug candidates in a number of areas including oncology, respiratory and infectious diseases.” Selvaraju noticed. The analyst continued, “We believe Movantik, Talicia and Aemcolo could have peak annual sales of $ 1.1 billion by 2028 alone. Opaganib, upamostat and RHB-204 – the only components of the extensive RedHill pipeline we currently have.” Model – Could add over $ 400M in revenue in the early 2030s, with RHB-204 potentially providing a sustained long-term revenue stream beyond 2040 if pending claims are granted, so we believe total sales of the products we forecast will RedHill could enable a> $ 1 billion revenue base over an extended period of time. “In line with his optimistic outlook, Selvaraju rates RDHL with a purchase and a target price of $ 23. That target suggests the stock will change hands in a year for a premium of 231%. (To view Selvaraju’s track record, click here.) Overall, based on all of the factors above, Wall Street analysts are impressed with RDHL. It offers 100% street support or 4 buy ratings in the last three months which makes the consensus a strong buy. The shares sell for $ 6.94 each, and the average target of $ 20.50 indicates a possible upward movement of 195% by next year. (See RDHL inventory analysis on TipRanks) Freeline Therapeutics (FRLN) The closest inventory, Freeline Therapeutics, is working on gene therapies for debilitating chronic diseases, including bleeding disorders. The company has four drugs in the development pipeline, two for the treatment of hemophilia, one for Fabry disease and one for Gaucher disease. Freeline pursues a proprietary liver-based gene therapy approach in its research. Three of the company’s drug candidates are in clinical trials. FLT190, which is being studied for the treatment of Fabry disease, is in a phase 1/2 dose-finding study. The data is expected to be submitted before the end of this year. FLT201 is also in a phase 1/2 dose-finding study for Gaucher disease. This study is expected to be in the clinic before the end of this year. Finally, FLT180a, a drug candidate being investigated for the treatment of hemophilia B, is in a Phase 1/2 dose confirmatory study and is well on its way to initiating trials by the end of the year. Among the cops is HC Wainwright analyst Patrick Trucchio, who is optimistic about the prospects for the company’s Gaucher program. “With limited competition, we believe the Gaucher program is Freeline’s most valuable program … Freeline presented positive data at the WORLD Symposium … We believe these data suggest that FLT201 may be able to provide a deliver sustained GCase expression in hard-to-reach areas.In addition, we believe that insights from data generated to date in the FLT180a and FLT190 programs in humans, particularly with regard to dosage and immunosuppression, could contribute to the FLT201 program Accelerate … We estimate that FLT201 could generate total sales of more than $ 8 billion. We estimate this program is valued at $ 12 / share on a risk-adjusted basis, “said Trucchio. The analyst summarized: “We believe that a recent sell-off of FRLN stock … ahead of data updates for the FLT180a, FLT190 and FLT201 created a compelling buying opportunity.” To this end, Driscoll rates FRLN a Buy along with a price target of $ 30. Should his thesis prevail, a potential upward trend of ~ 257% could be in the cards. (To see Trucchio’s track record, click here.) Trucchio isn’t the only one here taking an optimistic view. There are 6 recent reviews of this stock and all are positive, resulting in a unanimous Strong Buy consensus rating. The share price is $ 8.41, with an average target price of $ 24.50 representing an upward trend of 191%. (See FRLN stock analysis on TipRanks) Clene (CLNN) Finally, Clene, a clinical-stage biopharmaceutical company, is pursuing a unique path in the treatment of neurodegenerative diseases. The company uses nanotechnology to treat bioenergetic failure and the underlying factor in many neurological diseases. The company is developing bioenergetic nanocatalysts, a new class of drugs to accelerate neurorepair through energy-enhancing bioenergetic catalysis. In short, the company’s approach is to improve bio-functions at the cellular level so that the body can repair itself. Clene has four drug candidates in its pipeline. The lead, CNN-Au8, is described as a concentrated nanocrystalline gold (Au) suspension that triggers critical cellular bioenergetic responses in the central nervous system. CNN-Au8 is undergoing multiple concurrent clinical trials, including a phase 3 trial for amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease) and phase 2 trials for multiple sclerosis (MS) and Parkinson’s disease. All of these are progressive, chronic, degenerative conditions of the neuromuscular system. The phase 3 study with CNN-Au8 reached the 50% milestone in the first quarter. Full registration is expected before the end of this year and topline data is expected to be available in the first half of 22nd. Further updates to the company’s various other clinical study programs are planned for later this year. This company went public in December last year as part of a SPAC merger transaction. The merger with Tottenham Acquisition I Limited brought in proceeds of $ 31.9 million and resulted in the debut of CLNN shares on the NASDAQ on December 31 at $ 9.01 per share. With regard to CLNN for Cantor Fitzgerald, analyst Charles Duncan set an overweight rating (i.e., buy rating) and a target price of $ 22, indicating scope for the stock to appreciate ~ 129% from the current stock price of $ 9.63. (To see Duncan’s track record, click here.) “We see the unspecificity of ‘Au8 as positive for its broad applicability to a range of diseases in which oxidative stress and metabolic dysfunction are major drivers of pathophysiology. Although crystalline gold has long been believed to have metabolic activity, it was only then that we had to consider the convergence of profound scientific knowledge of nanocrystal technology with management skills in neurobiology and drug development The therapeutic potential of gold in treating neurodegenerative diseases, “said Duncan. The analyst added, “Clene owns a patented technology that enables gold nanocrystals to shape into specific shapes that are particularly useful in facilitating nanocatalytic activity and filtering toxic particles from the gold surface, promoting a differentiated clinical profile and possibly the Open the door to widespread use in medicine. “In its short time in the public markets, CLNN has received 4 analyst reviews – and all are positive, which makes analyst consensus a strong buy. The stock has an average price target of $ 22.25, which indicates a year-long upward movement of 131% from current levels. (See CLNN stock analysis on TipRanks.) To find good ideas for trading stocks at attractive valuations, visit TipRanks’ Best Stocks to Buy, ‘a newly launched tool that brings together all of TipRanks’ stock insights. Disclaimer: The opinions expressed in this article are solely those of the presented analysts. The content is intended to be used for informational purposes only. It is very important that you do your own analysis before making any investment.